TW323278B - - Google Patents
Download PDFInfo
- Publication number
- TW323278B TW323278B TW085103420A TW85103420A TW323278B TW 323278 B TW323278 B TW 323278B TW 085103420 A TW085103420 A TW 085103420A TW 85103420 A TW85103420 A TW 85103420A TW 323278 B TW323278 B TW 323278B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- cells
- tumor cells
- item
- ministry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Description
經濟部中央標準局員工消費合作社印製 323S78 at ____B7 _ 五、發明説明(1 ) 背景 國際公告編號WO 92/1 1034,1992.7.9公告,揭示增加腫 瘤對其具抗性之抗腫瘤劑之敏感度之方法,藉由同時投予 抗腫瘤劑及下式之增強劑:
式中Y'爲氫、經取代之羧酸酯或經取代之磺醯基。例如Y · 在其他眾多當中,可爲UCOOR',其中R·爲C1至C6烷基或 經取代烷基、苯基、經取代苯基、C 7至C 1 2芳烷基或經取 代芳烷基或-2,-3或-4六氫吡啶基或N-經取代六氫吡啶基 。Y’,於其他當中,亦可爲S02R,,其中R,爲C1至C6烷基 、苯基、經取代苯基、C 7至C 1 2芳烷基或經取代芳烷基。 此等增強劑之實例包括11-(4-亞六氫吡啶基)-5H-苯並[5,6] 雄庚[l,2-b]>»比淀如羅拉塔咬(Loratadine)。 爲獲得轉形之可能,Ras致癌基因必須進行位於羧基末端 之四肽之半胱胺酸殘基之法呢基化。催化此修·.飾作用之酵 素’法呢基蛋白質轉移酶之抑制劑,因此已被提議爲供其 中之Ras助成轉形之腫瘤用之抗癌劑。ras之突變、致癌形 式常發現於許多人類癌中,最顯著地於多於50〇/〇之結腸及 騰癌(Kohl等,Science,Vol. 260,1834 至 1837,1993)。 -4 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) I. I I 裝 —ιί 訂―J^ - . (請先聞讀背面之注意事項再填寫本頁) 經濟.那中夬標準局員工消費合作社印製
五、發明説明(3 )
A7 B7
經濟部中央標準局員工消費合作社印製
此等化合物用於本發明方法。用於本發明之較佳化合物由 式 801.00,802.00,803.00,804.00 及 805.00 表示。 本發明亦提供藉由投予有效量之本文所述之三環化合物 於須此治療之哺乳類(例如人類)而抑制腫瘤生長之方法。 -6 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 s^B278 Μ -------—__________一五、發明説明(4 ) - 特定言之,本發明提供藉由投予有效量之上述化合物而抑 制表現經活化之Ras致癌基因之腫瘤之生長之方法。可被 抑制之腫瘤之實例包括而不限於肺癌(例如肺腺癌).、胰臟 癌(例如外分泌胰癌之胰臟癌)' 結腸癌(例如結腸直腸癌如 結腸腺癌及結腸腺瘤)、脊髓白血病(例如急性脊髓性白血 病(AML)、甲狀腺濾泡癌、膀胱癌及脊髓發育不良症候群 (MDS)。 ' 咸信本發明亦提供抑制增生性疾病,良性與惡性於其中 Ras蛋白質由於於其他基因中之致癌性突變而被畸變性,活 化...亦即Ras基因本身並非藉由突變成致癌性形式而被活 化…之方法,該抑制作用係藉由投予有效量之本文所述之 三環化合物於須此治療之哺乳類(例如人類)而達成。例如 ,良性增生性疾患纖維神經瘤病,或其中Ras由於酪胺酸 激酶致癌基因(例如neu,src,ab卜lck,lyn,fyn)之突變或 過度表現而被活化之腫瘤,可藉由本文所述之三環化合物 而抑制。 本發明化合物抑制致癌基因蛋白質Ras之法呢基蛋白質轉 移酶及法呢基化。本發明另提供抑制哺乳類尤其人類中之 ras法呢基蛋白質轉移酶之方法,藉由投予有效量之上述之 三環化合物。投予本發明化合物於患者,抑制法呢基蛋白 質轉移酶,用於治療上述之癌。 用於本發明方法之三環化合物抑制不正常之細胞生長。 不希望爲理論所束縛,但咸信此等化合物可透過抑制G _蛋 白質功能如ras P21,藉由阻斷G -蛋白質異戊二晞化而發择 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨〇 x 2们公釐 (請先閲讀背面之注意事項再填寫本頁) -裝· '、*!. 線
、發明説明( 經濟部中央標準局員工消費合作社印製 功能,因此使彼等用於治療 了i 臂生性疾祸如腫瘤生長及疬。 不希望爲理論所束缚,作戍/、 y玍长夂知 白質轉移酶,且二:成= 曼jg之詳細説明 曰土占| 本發明之某些化合物可以 不同I異構(例如對掌異構物及 非對掌異構物)形式存在。本 奉發明涵蓋所有此種異構物,以 純的形式及以混合形式句拓认、必> 人, 括外4旋此合物。亦包括烯醇形 式。 本發明化合物可以未媒合及媒合形式存在,包括水合形 式例如半水合物。一般’媒合形式,與醫藥上可接受之溶 媒如水、Et〇H之類,供本發明之目的用,相等於未媒合形 式。 某些鹼性三環化合物亦形成醫藥上可接受之鹽,例如酸 加成鹽。例如吡啶基-氮原予可與強酸形成鹽,而具鹼性取 代基如胺基之化合物亦與較弱之酸形成鹽。適宜之供形成 鹽之酸之實例爲鹽酸、硫酸、磷酸、乙酸、檸檬酸、草酸 、丙二酸、水楊酸、蘋果酸'富馬酸、琥珀酸、抗壞血酸 、馬來酸、甲磺酸及已知於此道者之其他礦酸及叛酸。藉 由自由態驗形式與充分量之以習用方法製鹽所須之酸接觸 製備鹽。自由態鹼形式可藉由適宜之稀鹼水溶液如Na〇H、 K2C03、NH3及NaHC03稀水溶液處理鹽而再生。自由態驗 多少於某些物理性質如於極性溶媒中之溶解度,不同於其 各別之鹽形式,但酸及鹼鹽供本發明之目的用,相等於其 各別之自由態鹼形式。 -8 本紙浪尺度適用中國國家標準(CNS ) Α4規格(2丨〇 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝·
,1T 五 、發明説明(6 A7 B7 所有此等酸及鹼鹽爲於本發明之範圍内之醫藥上可接受 ^鹽,且所有酸及鹼鹽供本發明之目的用,被認爲相等於 對應化合物之自由態形式。 化合物 800.00 至 805 00 可藉 w〇 95/1〇515,1995 4 2〇 公告 ,所述之方法(例如參見對式400.〇〇所述之製備),及藉下面 實例中所述方法製備。 於實例中,MH+表質譜中之分予之分子離子加氫。而且 ’本.文提及之縮寫係指下面之溶媒及試劑;甲醇(Me〇H); 乙酸乙^(EtOAc);及N,N-二甲基甲醯胺(DMF)。 製備實例1 步驟A :
C1 經濟部令夬橾準局員工消費合作社印製
C1 ------举------1T------.^ (請先閲讀背面之注*·事f .填寫本頁) ) . < I. — I 1*—_1! ' ! ! 將50.0克(20.5毫莫耳)8-氯-5,6-二氫-11H-笨並[5,6]環庚 [l,2-b]吡啶_丨丨·酮冷卻至〇°c並於2〇分内慢慢加75毫升一 氣化疏。於15分内加25毫升(48.59毫莫耳)Βγ2,再於95»c 加熱2 0小時。於1 5分内加Βι*2並再加熱2 4小時。冷卻混合 -9 - 本纸張尺度適用中國國家標準(CNS ) A4規格(2ωχ297公釐) A7 B7
五、發明説明(7 物並慢慢加至〇 °c之CH2 Cl2與1 N NaOH(水溶液)之混合物 。以水洗有機相,於MgS04上乾燥並眞空濃縮至殘留物。 層析(矽膠,500 毫升 CH2C12,再 〇.2%-5%(10%濃NH4OH( 於 MeOH 中))-CH2Cl2),再層析(矽膠,3-8.5% EtOAc/己燒) 得8.66克產物化合物。質譜:河^1 + = 322。 步驟B :
° OH 合併6.84克(21.2¾莫耳)步驟A產物、160.5毫升MeOH, 再以1.1709克^8114如>^〇 95/10515之製備實例7,步驟八 所述處理,得5.93克產物化合物。MH+ 326 步驟C : -
C1 合併5.93克(18.3毫莫耳)之步驟B產物及i 16毫升無水甲 苯,冷卻至0°C,於0.5小時冶慢慢加(滴加)2 465克(33,9哀 莫耳)SOC12於23毫升無水甲苯中之溶液。於攪拌 時並於〇 _25 c攪拌2小時,再如wo 95/10S15之製備實例7, 步驟B所述處理,得產物化合物。 ’ 步驟D : 10- 木纸張尺度適财關家鮮(CNS ) A4規格( I I— i I —j- 1 裝 I. ; 訂, ^~ 線 (請先軋讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製
經濟部中央標準局員工消費合作社印製 I _____
Cl A7 B7 五、發明説明(
將18.3毫莫耳之步驟C產物與9.94克(91 ·5毫莫I)之/、氫 吡畊經由WO 95/1 05 15之製備實例7,步驟C中所述方法’ 得8.0克標題化合物。質譜:MH+=3 94 製備實例2
。〇 合併10克(31.9毫莫耳)之W0 95/1〇515之製備實例7,步 驟C之產物、100毫升無水<:%(:12並於〇.75小時内慢慢加( 滴加)5.17克(3 1.9毫莫耳)羰基二咪唑於1 5 0毫升無水 CH2C12中之混合物。於0°C攪拌2小時,以水洗,於MgS04 上乾燥、眞空濃縮至’殘留物。層析(矽膠,2%(10%濃 NH4OH,於MeOH中)/CH2Cl2)得8.71克標題化合物.。質譜 :MH + = 408.2 ° 用製備實例1,步驟D之產物及實質上如同製備實例2所 述之方法,製備下面化合物: * 11 * 本纸張尺度適用中國國家標準(CNS ) A4规格(210X297公瘦) ----------赛------1T------.^ (f先閱讀背面之注意事'j ..填寫本頁) < 323278 A7 B7
五、發明説明( 製備實例2-A 質譜:MH + = 488.2 复例3
H3G~N
COC1 合併1 0毫升無水CH2C12及914.6毫升(28.1毫莫耳)之光氣 於甲苯中之1.93M溶液’冷卻至〇。〇並於1 0分内慢慢加(滴 .加)0.6484克(5.62毫莫耳)3-羥基-1-N-甲基六氫吡啶、1.214 毫升(15毫莫耳)吡啶及10毫升無水CH2C12之溶液,再於〇。-X25°C攪拌2小時。以N2清除過量光氣,再眞空濃縮得標題 化合物。 實例1 髮ίτ線 (请先閱讀背面之注意事 > 填寫本育S' · ~ ._κ[_____ 經濟部中央標準局員工消費合作社印製
C1 本紙張尺度適用中國國家標準(CNS ) Α4规格(2丨0 X 297公釐) A7 B7 —一__ - 丨· . ~~" "" 五、發明説明(10) 合併12毫升無水CH2C12及12.5 8毫升(23.9毫莫耳)之光氣 於甲苯中之28%溶液,冷卻至〇°C (於Ar大氣下),並於0.75 小時内慢慢加(滴加)〇. 5克(1.59毫莫耳)之WO 95/105 15之 製備實例7,步驟c之產物' 0.5丨5毫升(6.36毫莫耳)吡啶及 1 2毫升無水CH2 Cl2之溶液,再於0.5小時内將混合物溫至1 2 °C。以Ar清除過量光氣,再眞空濃縮至殘留物。加10毫升 DMF、0.515毫升吡啶及0.885克(7.95毫莫耳)3-羥基吡啶-1-N-化氧並於2 5 °C攪拌1 8小時。以CH2 Cl2稀釋,以飽和 NaHC03 j(水溶液)洗,於MgS04上乾燥。眞空濃縮至殘留物 ,層析(矽膠,1·5%(1〇% NH4OH,於 MeOH 中)/CH2Cl2) 得0.186克標題化合物。質譜:ΜΗ+ = 45 1.3。 實例2 請先閱讀背面之注意事^馮填寫本頁) 訂
線 經濟部中央標準局員工消費合作社印製 合併0.1克(0.205毫莫耳)之製備實例2-Α產物、0.0463克 (0.205毫莫耳)ZnBr2、0.0913克(0.822毫莫耳)3-輕基吡啶_ 1-N-化氧及3毫升無水DMF,於90°C加熱51小時,再於25 °C攪拌I 9小時。眞空濃縮至殘留物並層析(矽膠,2 %(10% 1^^14011,於]^6〇11中)/(:112(:12),得〇.〇812克標題化合物 -13- 本紙張尺度適用中國國家標準(CNS‘)八4規格(21〇χ297公釐) 五、發明説明(11 ) A7 B7 。質譜:ΜΗ + = 531·1。用所指示之起始化合物及依實質上如同實例2所述之方法 ,得下面化合物:
經濟部中央標準局員工消費合作社印製
-14 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) I 裝 訂 線 < I (請先閱讀背面之注意事項爿填寫本頁) 經濟部中央標準局員.H消費合作杜印製 A7 __B7 五、發明説明(12 ) 實例3
合併0.5克(1.6毫莫耳)之W0 95/10515之製備實例7,步驟 C之產物y 0.849克(4.8毫莫耳)之製備實例3之標題化合物 及1 0毫升之1 : 1吡啶/CH2C12,於25X:攪拌1 9小時。如 WO 95/105 15之實例4所述處理及層析(矽膠,3%(1〇0/〇 NH4OH,於MeOH中)/CH2Cl2)得0.5231克標題化合物。質 譜:MH+=455.25 用所指示之起始化合物及依實質上如同實例3所述之方法 — 別^"線 (身先閣讀滑面之注意事沒 >寫本頁) - 一 ,得下面化合物:
本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 323278 A7 B7 五、發明説明(13 ) 用W0 95/10515中所述方法測定FPT 1(:5〇(藉活體外之酵 素測足之法呢基蛋白質轉移酶之抑制作用)及c〇s iC5〆基 於細胞之測定)。結果提供於下表丨。細胞Mat測定及活體内 .抗腫瘤研究可藉WO 95/1 05 15所述方法爲之。 表1 4匕合物 FPT Ι〇5〇(μΜ) COS IC5 0 (μ Μ) (800_00)實例 1 0.01-10 (801.00)實例 2 0.01-10 (802.00)實例 3 10-100 (803.00)實例 3-A 0.01-10 10-100 (804.00)實例 2-A 0.01-10 (805.00)實例 2-B 0.01-10 · 此等數據證明本發明化合物藉由部分純化之大鼠及人類 腦法呢基蛋白質轉移酶(FPT)爲有效之Ras_cvLs&呢基化 — 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事^,^寫本頁吣 • - - I I I I I- S . · -裝· 抑制劑。此等數據亦顯示有本發明化合物藉由部分純化之 大鼠腦法呢基蛋白質轉移酶(FPT)可被認爲爲有效 (Η:50<10μΜ)之Ras_CVLw^呢基化抑制劑…參見表i。 爲自本發明所述之化合物製備醫藥組合物,惰性之醫藥 上可接受之載劑可爲固體或液體。固體形式製劑包括粉末 鍵劑、可分散之顆粒 '膠囊1囊劑及栓劑。粉末及錠劑 =5至約70百分比之活性成分。適宜之固體載劑已知 “支藝,例如碳酸鎂、硬脂酸鎂、滑石 '糖、乳糖。錠劑 -16- 本紙張尺度適财)A4規格(21()ϋ^γ 五、發明説明( 14 A7 B7 、粉末、爲囊劑及膠囊可用爲適宜口服之固體劑型。 爲製備栓劑,首先將低这化之墁如脂肪酸甘油醋或可3 月曰(/昆σ物溶化,並藉擾拌將活性成分均勾地分教其中。 再將溶化之均勾混合物倒人合宜大小之塑模,令冷卻且因 此固化。 液拉开/式製劑包括溶液、懸浮液及乳液。作爲實例可舉 水或水-丙二醇溶液供腸外注射。 液體形式製劑亦可包括供鼻内给藥用之溶液。 適宜吸人用之氣溶膠製劑可包含溶液及以粉末形式之固 體’其可與醫藥上可接受之油域性壓㈣體併用。 =含者爲㈣形式㈣,其在臨床前轉變成液體形式 製劑供口服或腸外給藥。此等液體形式包括溶液液 及乳液。 “ 本發明化合物亦可爲經皮輸送。經皮组合物可採霜刊、 洗劑、氣溶劑及/或乳液之形式,且可包料如習用於;支藝 供此目的用之基質之經皮貼布或貯存型中。 較佳地,將化合物經口投藥。 較佳地,醫藥製劑以單位劑量形式。於此等形. 製劑亞分成含適當量之活性組份例如有效於\ ^ , 之量之單位劑量。. 、lj所須目的 於製劑之單位劑量中之活性化合物之量可毫克至 1000¾克,更佳地由約i毫克至30〇毫克 化或調整。 ”疋應用而變 所用之眞正劑量可依患者之須要及待治療切況 -17 本紙張认適用中關家標準(CNS) M規格(別χ 297^ 請 先 閲 讀 背 面 之 注 意 事 項 再 填 寫 本 頁 裝 訂 經濟部中央標準局員工消費合作社印策 五、發明説明(15 A7 B7 ί·生而異。對特(情況之適當劑量之決定爲技藝之技術範圍 内 般,以少於化合物之最適劑量之較少劑量開始治療 之後,以小疋增量增加劑量,至達在情況下最佳之作用 。爲方便,可將總每日劑量分割,若須要在一日當中分成 部分給藥。 、本發明化合物及其醫藥上可接受之鹽之投藥量及次數, 依王治醫師考量此等因素如患者之年齡、情況及大小以及 待治療之症候之嚴重性判斷而調節。典型之推薦劑量療法 爲口服由10毫克至2〇〇〇毫克/日,較佳1〇至1〇〇〇毫克/曰, 分成2至4個劑量來阻斷腫瘤生長。當在以劑範圍内給藥時 ’此等化合物爲無毒性的。 下面爲含本發明化合物之醫藥劑量形式之實例。本發明 於此.醫藥組合物方面之範圍並不受所提供之實例之限制。 醫藥劑量形式實例 實例A _____ 錠劑 編號 成分 活性化合物 100 毫克/錠
(請先閱讀背面之注意事項再填寫本頁} 裝 -5 線 經濟部中央標準局員工消費合作社印製 2
乳糖U S P 玉米澱粉,食物級 純水中之1 0 %糊劑 爲 122 30
4 一玉米殿粉,食物級 硬脂酸鎂 總共 -18- 私紙張尺度適用中國國家標準(CMS ) A4規格(210 X 297公釐) 45 3 3 00
五、發明説明(16 )
將品目編號1及2於適宜混合器中混合10-15分。將混合物 與品目編號3製粒。研磨濕粒,若須要通過粗篩(例如1/4,, ’ 0.63公分)。乾燥濕粒。若須要將乾粒過篩再與品目编號 4化合’並混合1 〇_ 1 5分。加品目編號5並混合1 _ 3分。於適 瓦製錠機上壓縮混合物至適當大小及重量。 [------^ 實例B - 膠囊 _編號 成分 毫克/膠囊 毫克/膠囊 〜_____1 活性化合物 100 5 0 0 乳糖U S P 106 12 3 玉米澱粉,食物級 40 70 硬脂酸鎂NF 7 7. ------ 總共 253 700 (請先閱讀背珀之沭意事4-4填^本' .装· ΪΤ 經濟部中央榡準局員工消費合作杜印製 皇造方法 將品目編號1、2及3於適宜摻合器中混合分。加品 目編號4並混合1-3分。於適宜包膠機上充填混合物於適宜 之兩片硬明膠膠囊中。 雖然將本發明連同上述之特殊具體實施例加以陳述,但 其终多替代法、修飾法及變化法顯然於精於此道者。所有 此等替代法,修飾法及變化法皆落在本發明之主旨及範圍 内。 -19- 本纸張尺度適用中國國家標準(CNS ) Μ規格(210X 297公釐) 衣年月 -¾¾. , Z ~ 修正 痛充 第八五一〇三四二〇號專利_請案 中文補充説明書(八十六年八月) C-13NMR 數據: 式 800.00 δ〇 (CDCI3) 三環部份 CH2: CH: C: 30.0, 30.1 145.9, 138.9, 130.1, 122.9, 125.8, 132.2, 79.0 140.9, 133.7, 135.3, 134.6, 156.4 六氫吡畊 ch2: 43.7, 44.1, 50.4, 50.6 六氫ρ比啡 N-取代基 CH: C: 119.8, 133.9, 135.9, 124.7 \ 149.7, 151.2 式 801.00 5c (CDCI3) 三環部份 CH2: CH; C: 29.9, 29.8 - 146.8, 141.0, 132.0, 130.2, 126.0, 78.4 119.7, 140.6, 134.0, 134.8, T36.5, 155.1 六氫'^比"^ CH2: 43.6, 44.0, 50.4, 50.6 六氫》比命丨 N:取碰 CH: C: 119.7, 133.9, 136.0, 124.8 149.6, 151.2 式 804.00 δ〇 (CDCI3) 三環部扮 CH2: CH: C: 29.8, 30.0 145.8, 138.6, 130.0, 122.7, 125.6, 132.1, 79.3 140.8, 133.4, 135.7, 134.4, 156.9 六氫吡畊 ch2: 43.1,43.1, 50.7, 50.7 六氫吡啡1, Ν-取代基 ch3: CH2: CH: C: 45.6 59.0, 28.5, 22.0, 54.7 69.7 154.5 U: \ΤΥ?Σ\ϋ7Ύ\ΜΤΥ-228.DOC\31 1 式 805.00 5c (CDCI3) - CH2: 29.7, 29.8 三環部份 CH: 145.7, 140.9, 132.1, 125.8, 130.2, 78.6 C: 119.5, 140.5, 133.8, 135.2, 136.4, 155.7 六氫〃比_ CH2: 43.1, 43.1, 50.7, 50.7 ~ ' CH3: 45.7 六氫p比啡、.: CH2: 59.1,28.6, 22.1, 54,7 N-取代基 CH: 69.8 C: 154.5 式 802.00 6c (CDCI3) CH2: 29.9, 30.1 三環部份 CH: 145.9, 138.7, 130.1, 122.7, 125.6, 132.2. 79.3 . C: 140.9, 133.5, 135.7, 134.5, 156.9 六氫'^比51 井 CH2: 43.1, 43.1, 50.7, 52.2 CH3: 45.5 六負/比哨: CH2: 50.7, 50.7,30.4, 30.4 Ν-取代基 CH: 69.5 C: 154.5 式 803.00 δ〇 (CDCI3) 三環部份 CH2: CH: C: 29.7 29.8 145.7, U0.9, 132.1, 125.8, 130.2, 78.6 119.5, 140.5, 133.8, 135.2, 136.4, 155.7 六氫峨_ CH2: 43.1, 43.1, 50.7, 50.7 六氫吡畊 Ν-取代基 CH3; CH2: CH: C: 45.7 59.1,28.6, 22.1, 54.7 69.8 154.5 U:\TYPE\MTY\MFY-228.DOC\31 2
Claims (1)
- 丨補充 im $420號專利申請案 会88: :青專利範圍修正本(86年8月)g88 々、申請專利範圍 1. 一種抑制細胞之不正常生長之醫藥組合物,其包含醫藥 可接受載劑及有效量量之選自以下之化合物:(請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印^ 2. 根據申請專利範圍第1項之醫藥組合物,其中受抑制之 細胞爲表現經活化之R a s致癌基因之腫瘤細胞。 3. 根據申請專利範圍第2項之醫藥組合物,其中受抑制之 細胞爲跋腫瘤細胞、肺癌腫瘤細胞、上皮癌腫瘤細胞、 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)、、申請專利範圍 脊Μ白血病腫瘤細胞、甲狀腺濾泡腫瘤细胞、脊髓發育 不良細胞' 膀胱癌腫瘤細胞或結腸腫瘤細胞。 根據申請專利範園第1項之醫藥組合物,其中細胞之不 疋常生長之抑制作用係藉由抑制法呢基蛋白質轉移酶。 ’根據申請專利範圍第1項之醫藥組合物,其中該抑制作 用係屬於於其中之Ras蛋白質由於於除了 Ras基因以外之 基因中之致癌性突變而被活化之腫瘤細胞。 6· ~'種化合物,其係選自下式:-2- 本紙張尺度通用中國國家標準(CNS ) A4規格(210X297公釐) 裂 i J~·^ ί ' ( (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 A8- B8 C8 D8 32327#^. ί 表年月a _!蝻 #. 86. 9 申請專利範圍 7. 根據申請專利範圍第6項之化合物,其係用於製造用於 抑制不正常細胞生長之藥劑。 8. 根據申請專利範圍第6項之化合物,其係用於抑制不正 常細胞之生長。 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -3- 本紙浪尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/410,479 US5721236A (en) | 1993-10-15 | 1995-03-24 | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
TW323278B true TW323278B (zh) | 1997-12-21 |
Family
ID=23624909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085103420A TW323278B (zh) | 1995-03-24 | 1996-03-21 |
Country Status (15)
Country | Link |
---|---|
US (4) | US5721236A (zh) |
EP (1) | EP0817632B1 (zh) |
JP (1) | JP3001983B2 (zh) |
KR (1) | KR19980703250A (zh) |
AR (1) | AR001413A1 (zh) |
AT (1) | ATE232101T1 (zh) |
AU (1) | AU714308B2 (zh) |
CA (1) | CA2216231C (zh) |
DE (1) | DE69626104T2 (zh) |
ES (1) | ES2187642T3 (zh) |
IL (1) | IL117601A0 (zh) |
MX (1) | MX9707192A (zh) |
NZ (1) | NZ304641A (zh) |
TW (1) | TW323278B (zh) |
WO (1) | WO1996030018A1 (zh) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
NZ326035A (en) * | 1995-12-22 | 2000-01-28 | Schering Corp | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
US6117641A (en) | 1996-04-11 | 2000-09-12 | Mitotix, Inc. | Assays and reagents for identifying anti-fungal agents and uses related thereto |
US6727082B1 (en) | 1996-04-11 | 2004-04-27 | Gpc Biotech Inc. | Assays and reagents for identifying anti-fungal agents, and uses related thereto |
JP2001513622A (ja) | 1996-04-11 | 2001-09-04 | マイトティックス インコーポレーテッド | 抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用 |
US5925757A (en) * | 1996-07-26 | 1999-07-20 | Schering Corporation | Method for preparing carboxamides |
US6040305A (en) * | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6030982A (en) | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
CA2266015C (en) * | 1996-09-13 | 2003-12-30 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
US5994364A (en) * | 1996-09-13 | 1999-11-30 | Schering Corporation | Tricyclic antitumor farnesyl protein transferase inhibitors |
US5945429A (en) * | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US5861395A (en) * | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
US5985879A (en) * | 1996-09-13 | 1999-11-16 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
US6130229A (en) * | 1996-10-09 | 2000-10-10 | Schering Corporation | Tricyclic compounds having activity as RAS-FPT inhibitors |
US6689789B2 (en) * | 1997-06-17 | 2004-02-10 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US5877177A (en) * | 1997-06-17 | 1999-03-02 | Schering Corporation | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6239140B1 (en) | 1997-06-17 | 2001-05-29 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6576639B1 (en) | 1997-06-17 | 2003-06-10 | Schering Corporation | Compounds for the inhibition of farnesyl protein transferase |
US6159984A (en) * | 1997-06-17 | 2000-12-12 | Schering Corporation | Farnesyl protein transferase inhibitors |
US6051582A (en) * | 1997-06-17 | 2000-04-18 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
US5939416A (en) * | 1997-06-17 | 1999-08-17 | Schering Corporation | Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors |
US6218401B1 (en) | 1997-06-17 | 2001-04-17 | Schering Corporation | Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase |
US6632455B2 (en) | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
JP2002530436A (ja) * | 1998-11-25 | 2002-09-17 | ジェネティカ インコーポレイテッド | 増殖能を増強しかつ複製老化を防止する方法及び試薬 |
US6271378B1 (en) | 1998-12-18 | 2001-08-07 | Schering Corporation | Process for preparing tricyclic compounds having antihistaminic activity |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2001051126A1 (en) | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO2001051128A1 (en) | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6566385B2 (en) | 2000-01-12 | 2003-05-20 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6610722B2 (en) | 2000-04-10 | 2003-08-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US7342016B2 (en) * | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
FR2813891B1 (fr) * | 2000-09-14 | 2005-01-14 | Immunotech Sa | Reactif multifonctionnel pour erythrocytes mettant en jeu des carbamates et applications |
CZ2004714A3 (cs) * | 2001-12-14 | 2004-10-13 | Novoánordiskáa@S | Sloučeniny a jejich použití ke snížení aktivity lipázy citlivé vůči hormonu |
EP1656156A2 (en) | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
CA2663436A1 (en) * | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
PL2336120T3 (pl) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP) |
MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
CA2685967A1 (en) | 2007-05-21 | 2008-11-21 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
PE20121172A1 (es) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | Piperidinas sustituidas con actividad en la hdm2 |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
BR112012023021A2 (pt) | 2010-03-16 | 2016-05-31 | Dana Farber Cancer Inst Inc | compostos de indazol e seus usos |
US8999957B2 (en) | 2010-06-24 | 2015-04-07 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as ERK inhibitors |
CA3186328A1 (en) | 2010-07-28 | 2012-02-02 | Janssen Pharmaceutica Nv | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
IN2013MN02170A (zh) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP3569598A1 (en) | 2011-11-17 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
EP2951180B1 (en) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の阻害剤 |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CN108371711A (zh) | 2015-08-17 | 2018-08-07 | 库拉肿瘤学公司 | 使用法尼基转移酶抑制剂治疗癌症患者的方法 |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
SG11201903786UA (en) | 2016-11-03 | 2019-05-30 | Kura Oncology Inc | Farnesyltransferase inhibitors for use in methods of treating cancer |
MX2019012233A (es) | 2017-04-13 | 2020-01-14 | Aduro Biotech Holdings Europe Bv | Anticuerpos anti-sirpa. |
WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
CN112341433A (zh) * | 2020-11-16 | 2021-02-09 | 成都大学 | 一种氯雷他定的制备方法 |
CN115385892A (zh) * | 2021-10-28 | 2022-11-25 | 天津市昕晨投资发展有限公司 | 地氯雷他定衍生物、其制备方法及其用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4355036A (en) * | 1980-06-19 | 1982-10-19 | Schering Corporation | Tricyclic-substituted piperidine antihistamines |
US4282233B1 (en) * | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
US4826853A (en) * | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
ATE141599T1 (de) * | 1988-04-28 | 1996-09-15 | Schering Corp | Kondensierte polyzyklische verbindungen, zusammenstellungen, verfahren zur herstellung und deren anwendung als paf-antagonistische, antihistaminische und/oder anti-inflammatorische agenzien |
US5104876A (en) * | 1988-04-28 | 1992-04-14 | Schering Corporation | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use |
US4863931A (en) * | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
US5141851A (en) * | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
US6083917A (en) * | 1990-04-18 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions for the identification, characterization and inhibition of farnesyltransferase |
ZA914764B (en) * | 1990-06-22 | 1992-03-25 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use |
DE69120430D1 (de) * | 1990-12-18 | 1996-07-25 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
KR920014799A (ko) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
US5340828A (en) * | 1991-09-30 | 1994-08-23 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5643909A (en) * | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
GB2296717B (en) * | 1993-10-15 | 1998-05-20 | Danisco | Use of an enzyme |
IL111258A0 (en) * | 1993-10-15 | 1994-12-29 | Schering Corp | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
-
1995
- 1995-03-24 US US08/410,479 patent/US5721236A/en not_active Expired - Fee Related
- 1995-05-31 US US08/455,018 patent/US5728703A/en not_active Expired - Fee Related
-
1996
- 1996-03-21 TW TW085103420A patent/TW323278B/zh active
- 1996-03-21 MX MX9707192A patent/MX9707192A/es not_active IP Right Cessation
- 1996-03-21 DE DE69626104T patent/DE69626104T2/de not_active Expired - Fee Related
- 1996-03-21 WO PCT/US1996/003312 patent/WO1996030018A1/en active IP Right Grant
- 1996-03-21 AU AU51891/96A patent/AU714308B2/en not_active Ceased
- 1996-03-21 IL IL11760196A patent/IL117601A0/xx unknown
- 1996-03-21 AT AT96908751T patent/ATE232101T1/de not_active IP Right Cessation
- 1996-03-21 CA CA002216231A patent/CA2216231C/en not_active Expired - Fee Related
- 1996-03-21 KR KR1019970706654A patent/KR19980703250A/ko not_active Application Discontinuation
- 1996-03-21 NZ NZ304641A patent/NZ304641A/en unknown
- 1996-03-21 ES ES96908751T patent/ES2187642T3/es not_active Expired - Lifetime
- 1996-03-21 EP EP96908751A patent/EP0817632B1/en not_active Expired - Lifetime
- 1996-03-21 JP JP8529432A patent/JP3001983B2/ja not_active Expired - Fee Related
- 1996-03-22 AR AR33588896A patent/AR001413A1/es unknown
-
1997
- 1997-11-14 US US08/971,099 patent/US5977128A/en not_active Expired - Fee Related
-
1999
- 1999-07-07 US US09/348,916 patent/US6300338B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3001983B2 (ja) | 2000-01-24 |
US5728703A (en) | 1998-03-17 |
MX9707192A (es) | 1997-11-29 |
JPH10505103A (ja) | 1998-05-19 |
IL117601A0 (en) | 1996-07-23 |
DE69626104D1 (de) | 2003-03-13 |
EP0817632B1 (en) | 2003-02-05 |
US5977128A (en) | 1999-11-02 |
AU5189196A (en) | 1996-10-16 |
CA2216231C (en) | 2001-07-03 |
AR001413A1 (es) | 1997-10-22 |
ATE232101T1 (de) | 2003-02-15 |
US6300338B1 (en) | 2001-10-09 |
AU714308B2 (en) | 1999-12-23 |
EP0817632A1 (en) | 1998-01-14 |
NZ304641A (en) | 1999-04-29 |
ES2187642T3 (es) | 2003-06-16 |
DE69626104T2 (de) | 2003-11-27 |
WO1996030018A1 (en) | 1996-10-03 |
KR19980703250A (ko) | 1998-10-15 |
US5721236A (en) | 1998-02-24 |
CA2216231A1 (en) | 1996-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW323278B (zh) | ||
CN110183422B (zh) | 核转运调节剂及其用途 | |
TW473477B (en) | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
CN102171214B (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
TWI259081B (en) | Treatment of acute myeloid leukemia with indolinone compounds | |
JP6963312B2 (ja) | 超強力ビンカアルカロイド:付加された分子の複雑さがチューブリンの二量体−二量体界面を更に破壊する | |
RU2262339C2 (ru) | Производные индолил-3-глиоксиловой кислоты - соединения, обладающие противоопухолевой активностью, фармацевтическая композиция, противоопухолевое средство (варианты) | |
EP3569602B1 (en) | Imidazopyrazine compound, preparation method therefor and use thereof | |
KR20190099209A (ko) | 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물 | |
KR20130089264A (ko) | 헤테로사이클릭 유도체, 이의 제조 방법 및 이의 의학적 용도 | |
EP3466962A1 (en) | Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof | |
MX2014014582A (es) | Inhibidores pirazolopirimidona y pirazolopiridona de tanquirasa. | |
JP4464814B2 (ja) | アントラニル酸誘導体の水和物の製造方法 | |
CN115433187B (zh) | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 | |
EP3502103B1 (en) | Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor | |
WO2023025116A1 (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
TW201002688A (en) | Pharmaceutical compounds | |
JP2021191782A (ja) | 置換5,6−ジヒドロ−6−フェニルベンゾ[f]イソキノリン−2−アミンを調製するための方法 | |
CN117580839A (zh) | 抗癌核激素受体靶向化合物 | |
NZ506476A (en) | Substituted bisindolymaleimides for the inhibition of cell proliferation | |
US20230391765A1 (en) | Heterobifunctional compounds as degraders of enl | |
WO2022217042A1 (en) | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions | |
JPH11510822A (ja) | チロシンキナーゼ抑制剤としての置換テトラリルメチレン−オキシインドール同族体 | |
WO2022021785A1 (zh) | 一种含有tsl-1502m的药物组合物及其应用 | |
CN115403583A (zh) | 一种靶向降解fak蛋白的化合物及其用途 |